Latest Strategy News

Energy Resources of Australia reported a $47.1 million cash outflow from operations and a $75.4 million investment spend in the September quarter, reducing cash reserves to $108.3 million.

Energy Resources of Australia updates on ongoing legal battles over Jabiluka lease and compulsory acquisition, while Ranger rehabilitation faces delays and potential cost overruns.

Whitefield Income Limited has announced fully franked monthly dividends of 0.583 cents per share for the final quarter of 2025, delivering an 8.0% annual yield based on its IPO price.

ClearVue Technologies has raised A$4.6 million in a strongly supported placement to accelerate international certification and ongoing innovation of its solar façade products.

Ballymore Resources has identified significant shallow copper-gold mineralisation at its Andromache prospect through a recent induced polarisation survey, setting the stage for upcoming drilling campaigns across multiple Queensland projects.

Broken Hill Mines Limited has locked in a binding underwriting agreement for its BHMO Options, aiming to raise approximately A$7.5 million to accelerate drilling and development at its Broken Hill projects.

Sultan Resources has completed a $1 million strategic placement at a premium, positioning itself for key acquisitions and exploration in Namibia and Western Australia.

Locksley Resources has upgraded its U.S. trading status to the OTCQX Best Market, enhancing its visibility among American investors and reinforcing its strategic focus on critical minerals at the Mojave Project in California.

Advance Metals has unveiled an ambitious growth strategy to double its silver-equivalent resource base in Mexico to over 200 million ounces, backed by fresh funding and a suite of exploration initiatives across three high-grade projects.

AdAlta Limited has raised up to A$0.5 million through a premium-priced private placement, bolstering its 'East to West' cellular immunotherapy strategy focused on advancing CAR-T therapies for solid cancers.

Litchfield Minerals has reported a significant copper-zinc sulphide intercept exceeding 100 metres at its Oonagalabi Project, with ongoing drilling targeting major geophysical anomalies that could expand the resource.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.